What if you could screen billions of potential therapies—virtually—in the time it takes to brew your morning coffee?
In this episode of scientifica sessions, host Tabari Baker sits down with Tom Neyarapally, CEO and co-founder of Archetype Therapeutics, to explore how AI-native biotech is redefining what's possible in early-stage drug discovery. With a background that spans law, business, and executive leadership at companies like Sema4, Tom offers a rare vantage point on how data, machine learning, and strategic insight converge to accelerate breakthroughs in oncology and beyond.
Tom breaks down the science behind generative chemogenomics, a novel platform that Archetype uses to computationally model and prioritize billions of molecules against real-world patient data. He shares how this approach is opening new doors for underserved populations—starting with patients facing non-small cell lung cancer—and gives an insider's look at the challenges of validating AI-driven assets in a tightly regulated environment.
From AI-driven virtual screens to pragmatic lessons on leading AI-first biotech startups, this episode is a masterclass for executives navigating the future of translational science. If you're in biotech, pharma, or diagnostics—and responsible for building what's next—this conversation will leave you rethinking how you approach discovery, evidence, and leadership.
Tom Neyarapally is the CEO and Co-Founder of Archetype Therapeutics, an AI-native company pioneering the use of generative chemogenomics in patient data-driven drug R&D in cancer and other diseases. Previously, Tom was CCO and founding team member at Sema4, a patient-centered health intelligence and genetic testing company that went public in 2021. He was also a member of the founding team and EVP, Corporate Development at the causal AI drug discovery company Aitia.
After graduate school, Tom served as a corporate and IP lawyer at Chadbourne Parke LLP and Frommer Lawrence & Haug LLP. He started his career after college as an analyst focused on pharmaceuticals at the management consulting firm Arthur D. Little.
Tom earned a B.S. in chemical engineering (Honors Scholar/cum laude) from the University of Connecticut and a J.D. and M.B.A. from Cornell University. His unique combination of technical, legal, and business expertise provides him with a distinctive perspective on navigating the intersection of AI innovation and pharmaceutical development in highly regulated environments.
Connect with Tom:
If this conversation sparked new ideas or made you rethink how you align discovery with downstream strategy, subscribe to scientifica sessions. We bring you the leaders shaping what's next in biotech, medtech, and pharma. Connect with us at podcast@kronosscientifica.com.
Episode recorded on July 25, 2025.
scientifica sessions is produced by kronos scientifica, exploring the intersection of innovation, evidence, and strategy in life sciences.
At scientifica sessions, we love our music! Here's are the original tracks used:
Opening - scientifica sessions Theme
00:07:28 - Drift
00:19:44 - Breathe
00:45:54 - The Turning
Closing - scientifica sessions Theme
Like what you heard? Check out our producers, Thread and Tensor.